

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	116266	promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:35			0
2	BRS	L2	5516	constitutive adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:35			0
3	BRS	L5	625	molecular adj switch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:56			0
4	BRS	L7	0	5 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:36			0
5	BRS	L6	2	5 same 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:36			0
6	BRS	L8	91	(edwards adj cynhia.in.) or (fry adj kirk.in.) or (btrice adj thomas.in.) or (starr adj douglas.in.) or (laurance adj megan.in.) or (kwok adj	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:55			0
7	BRS	L9	0	5 and 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
8	BRS	L10	256	gene adj switch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
9	BRS	L11	0	10 and 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
10	BRS	L12	1873	regulatable adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0
11	BRS	L13	2	5 same 12	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:42			0
12	BRS	L14	2	5527690.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0
13	BRS	L15	0	12 and 14	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
14	BRS	L16	13445	inducible adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
15	BRS	L17	1028	12 and 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
16	BRS	L18	0	14 and 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
17	BRS	L19	856	5 or 10	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:57			0
18	BRS	L20	17692	(transcription adj factor) or (transcriptional adj regulatory adj protein) or (transcriptional adj regulatory adj factor) or ( DNA adj binding adj protein)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:58			0
19	BRS	L21	3064	(inducer or compound) same (DNA adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:00			0
20	BRS	L22	1	19 same 20 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0
21	BRS	L23	14558	dna adj binding	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:04			0
22	BRS	L24	661	20 same 21 same 23	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:09			0
23	BRS	L25	14290	12 or 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:05			0
24	BRS	L26	0	24 same 25 same transgene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:06			0
25	BRS	L27	3688	adenovirus adj vector	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:07			0
26	BRS	L28	1381	adeno-associated adj virus adj vector	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:07			0
27	BRS	L30	0	29 same transgene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:10			0
28	BRS	L31	15255	reporter adj gene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:11			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
29	BRS	L32	0	29 same 31	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:11			0
30	BRS	L29	18	20 same 19 same 23	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:24			0
31	BRS	L33	0	29 same (12 or 16)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:24			0
32	BRS	L34	286	DNA adj binding adj sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:25			0
33	BRS	L35	11443	ul9 or NF-kappaB or gal4 or ZFHD1 or lacR or tetR lexa or (ecdysone adj receptor adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:27			0
34	BRS	L36	13319	vp16 or nf-kappaB or gal4 or tfe3 or itf1 or oct-1 or spl or oct-2 or nfy-a or itf or cmc or ctf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:31			0
35	BRS	L37	332178	kruppel or krab or kox-1 or tetR or even-skipped or lacR or engrailed or hairy or hes or groucho or tle or ring1 or ssb16 or ssb24 or tup1 or nabl or areb or e4bp4 or hoxa7 or ebna3 or mad or v-erbA	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:33			0
36	BRS	L38	2381	(36 or 37) same 20	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:35			0
37	BRS	L39	0	35 same 38 same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:36			0
38	BRS	L40	70	(repressor or activator) same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:37			0
39	BRS	L41	29	(repressor or activator) same 19 same 20	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:38			0
40	BRS	L42	0	41 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:38			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
41	BRS	L43	2	41 same (dna adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:40			0
42	BRS	L44	0	8 and 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:40			0
43	BRS	L45	101	dna adj binding adj compound	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0
44	BRS	L46	1	45 same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0

FILE 'MEDLINE' ENTERED AT 16:49:32 14 SEP 2003

FILE 'CAPLUS' ENTERED AT 16:49:32 ON 14 SEP 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:49:32 ON 14 SEP 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:49:32 ON 14 SEP 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:49:32 ON 14 SEP 2003  
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

=> s molecular switch  
L1 4398 MOLECULAR SWITCH

=> s gene switch  
L2 903 GENE SWITCH

=> s l1 or l2  
L3 5291 L1 OR L2

=> s (transcription factor) or (transcriptional regulatory protein) or (transcriptional regulatory  
4 FILES SEARCHED...  
L4 417831 (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN)  
OR (TRANSCRIPTIONAL REGULATORY FACTOR) OR (DNA BINDING PROTEIN)

=> s (inducer or compound)(p) (dna binding)  
L5 7538 (INDUCER OR COMPOUND)(P) (DNA BINDING)

=> s l3 (p) l4 (p) l5  
L6 6 L3 (P) L4 (P) L5

=> duplicate remove l6  
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L6  
L7 2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 1-2 ibib abs

L7 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1  
ACCESSION NUMBER: 2002635673 MEDLINE  
DOCUMENT NUMBER: 22282001 PubMed ID: 12395191  
TITLE: A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene  
construct permits real-time detection of promoter  
activation by exogenously administered mifepristone in  
vivo.  
AUTHOR: Yu Y A; Szalay A A  
CORPORATE SOURCE: Division of Human Anatomy, Loma Linda University School of  
Medicine, Loma Linda, CA 92350, USA.  
SOURCE: Mol Genet Genomics, (2002 Oct) 268 (2) 169-78.  
Journal code: 101093320. ISSN: 1617-4615.  
PUB. COUNTRY: Germany: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200212  
ENTRY DATE: Entered STN: 20021024  
Last Updated on STN: 20030105  
Entered Medline: 20021213

AB In this study, we used a steroid-induced promoter activation system as a  
\*\*\*molecular\*\*\* \*\*\*switch\*\*\* to study the exogenous activation of  
transgene expression. This promoter activation system consists of three  
components: (1) a steroidal \*\*\*inducer\*\*\* drug, mifepristone (RU486),  
which binds to (2) a chimeric \*\*\*transcription\*\*\* \*\*\*factor\*\*\*  
complex, consisting of the mutant human progesterone receptor fused to the  
yeast GAL4 \*\*\*DNA\*\*\* - \*\*\*binding\*\*\* domain and the activation  
domain of the herpes simplex virus protein VP16, and (3) a synthetic  
promoter, consisting of a series of GAL4 recognition sequences upstream of  
the adenovirus major late E1B TATA box, linked to a gene construct

(ruc-gfp) encoding a Renilla luciferase- Aequorea green fluorescent protein (GFP) fusion protein. Transcription of the promoter-myc gene cassette is activated by the drug (mifepristone)-bound chimeric \*\*\*transcription\*\*\* \*\*\*factor\*\*\* complex. Monitoring of induced gene expression was carried out using a low-light video camera and a UV microscope to detect luciferase and GFP, respectively. Using this activation system, we observed a 10- to 25-fold activation, depending on the \*\*\*inducer\*\*\* dose, of both luciferase and GFP expression in transiently transfected cells in comparison to cells that were not exposed to mifepristone. We further demonstrated activation of gene expression from the promoter activation system in live animals. The plasmids PAP CMV-GL914VPC'SV, carrying the chimeric \*\*\*transcription\*\*\* \*\*\*factor\*\*\* cassette, and plasmid p17x4-TATA-ruc-gfp, carrying the ruc-gfp reporter gene construct, were co-injected into limb muscles of nude mice. Following DNA injection, mifepristone (50 micro g/kg) was delivered by intraperitoneal injection. Thirty-six hours after DNA and mifepristone injection, significant Renilla luciferase activity was detectable in the limb muscles. The promoter activation system was also demonstrated in limb muscles and livers of nude mice that had received transplants of ex vivo-modified cells, which were transiently transformed with both the chimeric activator plasmid and the ruc-gfp reporter plasmid prior to implantation. Significant Renilla activity and GFP fluorescence were detected externally in limb muscles and in the livers of anesthetized animals that had received an intraperitoneal injection of \*\*\*inducer\*\*\*. This external monitoring method for observing inducible gene expression in live animals will facilitate experimental studies of fundamental questions of biological and therapeutic relevance. It will be especially valuable for the analysis of gene function at specific stages of animal development. The method should also be of general use in gene therapy, since it permits simultaneous monitoring of the expression levels of light-emitting proteins and therapeutic proteins originating from the activation of identical promoters.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:628284 CAPLUS  
 DOCUMENT NUMBER: 133:233573  
 TITLE: Inducible regulatory systems for control of gene expression  
 INVENTOR(S): Lim, Moon Young; Edwards, Cynthia A.; Fry, Kirk E.; Bruice, Thomas W.; Starr, Douglas B.; Laurance, Megan E.; Kwok, Yan  
 PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA  
 SOURCE: PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052179	A2	20000908	WO 2000-US5728	20000303
WO 2000052179	A3	20001221		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1165808	A2	20020102	EP 2000-913742	20000303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:  
 US 1999-122513P P 19990303  
 US 1999-154605P P 19990917  
 WO 2000-US5728 W 20000303

AB Inducible gene expression systems regulated by a ligand are described. The system includes a nucleic acid construct which has a DNA response sequence for a \*\*\*transcriptional\*\*\* \*\*\*regulatory\*\*\* \*\*\*protein\*\*\* operably linked to a promoter, a \*\*\*compd\*\*\* binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a \*\*\*DNA\*\*\* \*\*\*binding\*\*\* \*\*\*compd\*\*\*. In some cases, the \*\*\*mol\*\*\* \*\*\*switch\*\*\* system further includes a nucleic acid sequence encoding a \*\*\*transcriptional\*\*\* \*\*\*regulatory\*\*\* \*\*\*protein\*\*\* operably

linked to a second promoter. The invention further provides a method for screening \*\*\*compds\*\*\* for the ability to function in the \*\*\*mol\*\*\* system and thereby regulate gene expression.

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

L1 4398 S MOLECULAR SWITCH  
L2 903 S GENE SWITCH  
L3 5291 S L1 OR L2  
L4 417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN  
L5 7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)  
L6 6 S L3 (P) L4 (P) L5  
L7 2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> s dna binding

L8 254485 DNA BINDING

=> s l3 (p) l4

L9 362 L3 (P) L4

=> s l9 (p) l8

L10 105 L9 (P) L8

=> s transgene or (reporter gene)

L11 163288 TRANSGENE OR (REPORTER GENE)

=> s l10 (p) l11

L12 17 L10 (P) L11

=> s promoter

L13 572487 PROMOTER

=> s l12 (p) l13

L14 7 L12 (P) L13

=> duplicate remove l14

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L14

L15 3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)

=> s l15 not l7

L16 1 L15 NOT L7

=> d l16 1 ibib abs

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:545853 CAPLUS

DOCUMENT NUMBER: 135:148182

TITLE: Molecular switches II system comprising  
ligand-regulated DNA binding molecule and targeted DNA  
binding site and its use in screening for desired  
binding elements and gene regulation

INVENTOR(S): Choo, Yen; Ullman, Christopher Graeme; Moore, Michael

PATENT ASSIGNEE(S): Gendaq Limited, UK

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053479	A2	20010726	WO 2001-GB187	20010118
WO 2001053479	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2000073434 A1 20001207 WO 2000-GB2071 20000530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001000815 A1 20010104 WO 2000-GB2080 20000530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2000-1578 A 20000124  
GB 2000-1582 A 20000124  
WO 2000-GB2071 W 20000530  
WO 2000-GB2080 W 20000530  
GB 2000-29901 A 20001207  
GB 1999-12635 A 19990528

AB A \*\*\*gene\*\*\* \*\*\*switch\*\*\* system comprising (i) a target nucleic acid mol.; (ii) a nucleic acid binding mol. which binds to the target nucleic acid mol. in a manner modulatable by a ligand; and (iii) the ligand is described. The \*\*\*DNA\*\*\* - \*\*\*binding\*\*\* ligand can modulate the interaction of the other two elements of the system which may both be derived from random libraries. The system is particularly intended for use to identify nucleic acid binding mols., targeted nucleic acid binding sites and modulating ligands, and to regulate transcription from one or more \*\*\*promoters\*\*\* in gene regulation. The selection of derivs. of the middle zinc finger of the \*\*\*transcription\*\*\* \*\*\*factor\*\*\* Zif268 with altered \*\*\*DNA\*\*\* \*\*\*binding\*\*\* from a phage display library in the presence of small mols. including Distamycin A, or actinomycin D, or echinomycin is presented. The \*\*\*DNA\*\*\* \*\*\*binding\*\*\* activity of these isolated phage clones are also modulated by ligands and their use in gene regulation are tested in vitro binding assay. The zinc finger \*\*\*DNA\*\*\* \*\*\*binding\*\*\* domain is also converted to the catalytic domain of FokI restriction enzyme for ligand modulation. The isolated zinc finger clones and HSV VP16 activation domain fusion protein is prepd. and the modulation of its transcriptional activity by ligands is demonstrated with a \*\*\*reporter\*\*\* \*\*\*gene\*\*\* in vivo. Methods of isolating cognate target nucleic acids and screening for ligands, which affect the binding of a \*\*\*DNA\*\*\* \*\*\*binding\*\*\* mol. to its cognate DNA target, are described by using 434 repressor of phage 434. The zinc finger protein/drug/DNA microarrays are also provided for the selection purpose.

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

L1 4398 S MOLECULAR SWITCH  
L2 903 S GENE SWITCH  
L3 5291 S L1 OR L2  
L4 417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN  
L5 7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)  
L6 6 S L3 (P) L4 (P) L5  
L7 2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)  
L8 254485 S DNA BINDING  
L9 362 S L3 (P) L4  
L10 105 S L9 (P) L8  
L11 163288 S TRANSGENE OR (REPORTER GENE)  
L12 17 S L10 (P) L11  
L13 572487 S PROMOTER  
L14 7 S L12 (P) L13  
L15 3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)



```

L16          1 S L15 NOT L7
=> s (regulatable or inducible) (w) promoter
L17          7266 (REGULATABLE OR INDUCIBLE) (W) PROMOTER

=> s 112 (p) 117
L18          0 L12 (P) L17

=> s nf-kappaB
L19          23346 NF-KAPPAB

=> s u19 or gal4 or zfhd1 or lacr or tetr or lexa or (ecdysone receptor binding)
L20          20191 UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LEXA OR (ECDYSONE RECEPT
OR BINDING)

=> s 119 or 120
L21          43442 L19 OR L20

=> s vp16 or nf-kappaB or gal4 or tfe3 or itf1 or oct-1 or sp1 or oct-2 or nfy-a or itf2 or cmc
L22          83638 VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR
OCT-2 OR NFY-A OR ITF2 OR CMYC OR CTF

=> s kruppel or krab or kox-1 or tetr or even-skipped or lacr or engrailed o hairy or hes or grouc
L23          33096 KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR
ENGRAILED O HAIRY OR HES OR GROUCHO OR TLE OR RING1 OR SSB16 OR
SSB24 OR TUP1 OR NAB1 OR AREB OR E4BP4 OR HOXA7 OR EBNA3 OR MAD
OR V-ERBA

=> s (122 or 123) (p) 14
L24          35250 (L22 OR L23) (P) L4

=> s 121 (p) 18
L25          9870 L21 (P) L8

=> s 13 (p) 124 (p) 125
L26          8 L3 (P) L24 (P) L25

=> duplicate remove 126
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L26
L27          4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)

=> s 127 not (17 or 116)
L28          3 L27 NOT (L7 OR L16)

=> d 128 1-3 ibib abs

```

```

L28 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:927602 CAPLUS
DOCUMENT NUMBER: 138:20483
TITLE: An GHRH (somatoliberin) expression system inducible by
a ligand-specific Gene-Switch regulator protein and
therapeutic uses
INVENTOR(S): Nordstrom, Jeffrey L.; Draghia-Akli, Ruxandra
PATENT ASSIGNEE(S): Valentis, Inc., USA; Baylor College of Medicine
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002097099	A1	20021205	WO 2001-US17573	20010530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2001-294316P P 20010529				
AB The present invention provides for a regulated gene expression system for				

growth hormone releasing hormone ("GHRH") characterized by low basal expression and high specific inducibility. The inducible-expression system includes two expression cassettes. The first expression cassette includes a promoter driving the expression of a mol.-switch fusion protein which comprises a DNA binding domain, a transactivation domain and a ligand-binding domain. The fusion protein is characterized by an inability to auto-dimerize in the absence of an ligand-inducer. The second expression cassette includes the gene encoding GHRH controlled by an inducible promoter which is activated by the fusion protein dimerizing in the presence of the inducer and binding to the promoter. The present invention includes therapeutic methods for treating growth hormone-related deficiencies assocd. with the growth hormone pathway; growth hormone-related deficiencies assocd. with genetic disease; wasting symptoms assocd. with burn, trauma, cancer, AIDS, and bone loss, as in elderly, or post-fracture. By administering an exogenously supplied inducer the expression system can be activated and controlled.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:927555 CAPLUS

DOCUMENT NUMBER: 138:19945

TITLE: Estrogen receptor ligand binding domain variants and prepn. of novel ligands and use to construct mol. gene switches for pharmaceutical use

INVENTOR(S): Bracken, Kathryn Rene; De Los Angeles, Joseph E.; Huang, Ying; Kadan, Michael J.; Ksander, Gary M.; Zerby, Dennis B.

PATENT ASSIGNEE(S): Novartis AG, Switz.

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002097050	A2	20021205	WO 2002-US16946	20020531
WO 2002097050	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003143559 A1 20030731 US 2002-157899 20020531

PRIORITY APPLN. INFO.: US 2001-294839P P 20010531

AB Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective "mol. gene switches" is disclosed. Methods of regulating gene function using these switches are provided as are pharmaceutical compns. contg. the novel ligands.

L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:477732 CAPLUS

DOCUMENT NUMBER: 131:223928

TITLE: Development of gene-switch transgenic mice that inducibly express transforming growth factor .beta.1 in the epidermis

AUTHOR(S): Wang, Xiao-Jing; Liefer, Kristin M.; Tsai, Sophia; O'Malley, Bert W.; Roop, Dennis R.

CORPORATE SOURCE: Department of Cell Biology and Dermatology, Baylor College of Medicine, Houston, TX, 77030, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1999), 96(15), 8483-8488

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previous attempts to establish transgenic mouse models to study the functions of transforming growth factor .beta.1 (TGF.beta.1) in the skin

revealed controversial roles for TGF.beta.1 in epidermal growth (inhibition vs. stimulation) and resulted in neonatal lethality in one instance. To establish a viable transgenic model for studying functions of TGF.beta.1 in the skin, we have now developed transgenic mice, which allow focal induction of the TGF.beta.1 transgene in the epidermis at different expression levels and at different developmental stages. This system, termed "gene-switch," consists of two transgenic lines. The mouse loricrin vector targets the GLVPC transactivator (a fusion mol. of the truncated progesterone receptor and the GAL4 DNA binding domain), and a thymidine kinase promoter drives the TGF.beta.1 target gene with GAL4 binding sites upstream of the promoter. These two transgenic lines were mated to generate bigenic mice, and TGF.beta.1 transgene expression was controlled by topical application of an antiprogesterone. On epidermal-specific induction of the TGF.beta.1 transgene, the BrdUrd labeling index in the transgenic epidermis decreased 6-fold compared with controls. Induction of the TGF.beta.1 transgene expression also caused epidermal resistance to phorbol 12-myristate 13-acetate-induced hyperplasia, with a redn. in both epidermal thickness and BrdUrd labeling compared with those in controls. In addn., TGF.beta.1 transgene expression induced an increase in angiogenesis in the dermis. Given that the TGF.beta.1 transgene can affect both the epidermis and dermis, this transgenic model will provide a useful tool for studying roles of TGF.beta.1 in wound-healing and skin carcinogenesis in the future.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

```

L1      4398 S MOLECULAR SWITCH
L2      903 S GENE SWITCH
L3      5291 S L1 OR L2
L4      417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN
L5      7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)
L6      6 S L3 (P) L4 (P) L5
L7      2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8      254485 S DNA BINDING
L9      362 S L3 (P) L4
L10     105 S L9 (P) L8
L11     163288 S TRANSGENE OR (REPORTER GENE)
L12     17 S L10 (P) L11
L13     572487 S PROMOTER
L14     7 S L12 (P) L13
L15     3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16     1 S L15 NOT L7
L17     7266 S (REGULATABLE OR INDUCIBLE) (W) PROMOTER
L18     0 S L12 (P) L17
L19     23346 S NF-KAPPAB
L20     20191 S UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LOR (ECDYSONE RECEPTO
L21     43442 S L19 OR L20
L22     83638 S VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR
L23     33096 S KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR E
L24     35250 S (L22 OR L23) (P) L4
L25     9870 S L21 (P) L8
L26     8 S L3 (P) L24 (P) L25
L27     4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)
L28     3 S L27 NOT (L7 OR L16)

```

=> s lim moon/au  
L29 2 LIM MOON/AU

=> s edwards cynthia/au  
L30 5 EDWARDS CYNTHIA/AU

=> s fry kirk/au  
L31 24 FRY KIRK/AU

=> s bruice thomas/au  
L32 9 BRUICE THOMAS/AU

=> s starr douglas/au  
L33 2 STARR DOUGLAS/AU

=> s laurance magan/au  
L34 0 LAURANCE MAGAN/AU

=> kwok yan/au  
KWOK IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s kwok yan/au  
L35 26 KWOK YAN/AU

=> s l29 or l30 or l31 or l32 or l33 or l35  
L36 68 L29 OR L30 OR L31 OR L32 OR L33 OR L35

=> s l36 and l1  
L37 1 L36 AND L1

=> s l37 not l7  
L38 0 L37 NOT L7

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
16:49:32 ON 14 SEP 2003

L1 4398 S MOLECULAR SWITCH  
L2 903 S GENE SWITCH  
L3 5291 S L1 OR L2  
L4 417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN  
L5 7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)  
L6 6 S L3 (P) L4 (P) L5  
L7 2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)  
L8 254485 S DNA BINDING  
L9 362 S L3 (P) L4  
L10 105 S L9 (P) L8  
L11 163288 S TRANSGENE OR (REPORTER GENE)  
L12 17 S L10 (P) L11  
L13 572487 S PROMOTER  
L14 7 S L12 (P) L13  
L15 3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)  
L16 1 S L15 NOT L7  
L17 7266 S (REGULATABLE OR INDUCIBLE) (W) PROMOTER  
L18 0 S L12 (P) L17  
L19 23346 S NF-KAPPAB  
L20 20191 S UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LOR (ECDYSONE RECEPTO  
L21 43442 S L19 OR L20  
L22 83638 S VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR  
L23 33096 S KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR E  
L24 35250 S (L22 OR L23) (P) L4  
L25 9870 S L21 (P) L8  
L26 8 S L3 (P) L24 (P) L25  
L27 4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)  
L28 3 S L27 NOT (L7 OR L16)  
L29 2 S LIM MOON/AU  
L30 5 S EDWARDS CYNTHIA/AU  
L31 24 S FRY KIRK/AU  
L32 9 S BRUCE THOMAS/AU  
L33 2 S STARR DOUGLAS/AU  
L34 0 S LAURANCE MAGAN/AU  
L35 26 S KWOK YAN/AU  
L36 68 S L29 OR L30 OR L31 OR L32 OR L33 OR L35  
L37 1 S L36 AND L1  
L38 0 S L37 NOT L7

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
194.07

TOTAL  
SESSION  
194.28

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY  
-3.26

TOTAL  
SESSION  
-3.26

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:11:25 ON 14 SEP 2003